Search results for "Protocols"

showing 10 items of 782 documents

A Decision Support Tool for Appropriate Glucose-Lowering Therapy in Patients with Type 2 Diabetes

2015

Contains fulltext : 152084.pdf (Publisher’s version ) (Open Access) BACKGROUND: Optimal glucose-lowering therapy in type 2 diabetes mellitus requires a patient-specific approach. Although a good framework, current guidelines are insufficiently detailed to address the different phenotypes and individual needs of patients seen in daily practice. We developed a patient-specific decision support tool based on a systematic analysis of expert opinion. MATERIALS AND METHODS: Based on the American Diabetes Association (ADA)/European Association for the Study of Diabetes (EASD) 2012 position statement, a panel of 12 European experts rated the appropriateness (RAND/UCLA Appropriateness Method) of tre…

medicine.medical_specialtyDecision support systemEndocrinology Diabetes and Metabolism[SDV]Life Sciences [q-bio]MEDLINEType 2 diabetesComorbidityHypoglycemiaGlucagon-Like Peptide-1 ReceptorBody Mass IndexEndocrinologyLife ExpectancyClinical ProtocolsInternal medicineHealth careReceptors GlucagonMedicineHumansHypoglycemic AgentsInsulinPrecision MedicineIntensive care medicineExpert TestimonyReimbursementComputingMilieux_MISCELLANEOUSGlycated HemoglobinDipeptidyl-Peptidase IV InhibitorsPioglitazonebusiness.industryDrug SubstitutionType 2 Diabetes MellitusMetabolic Disorders Radboud Institute for Molecular Life Sciences [Radboudumc 6]Original ArticlesPrecision medicinemedicine.diseaseDecision Support Systems ClinicalHypoglycemiaMetformin3. Good healthEuropeMedical Laboratory TechnologyEndocrinologySulfonylurea CompoundsDiabetes Mellitus Type 2Drug Therapy CombinationThiazolidinedionesbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
researchProduct

Nationwide Analysis on Surgical Staging Procedures and Systemic Treatment for Patients With Endometrial Cancer in Germany

2012

ObjectiveIn 2009 and 2006, the Arbeitsgemeinschaft Gynäkologische Onkologie evaluated therapeutic approaches for endometrial carcinoma (EC) in Germany.Methods and MaterialsA questionnaire was developed and sent to 775 German gynecologic departments in 2009 (500 in 2006). The results of the questionnaires were compared with each other and with the recommendations of the Arbeitsgemeinschaft Gynäkologische Onkologie’s guideline. Subgroup analyses were performed, dividing the participating centers into small and large centers and into centers with less and more experience with EC.ResultsResponses were available in 33.3% in 2009 and 35.8% in 2006. Comparing 2009 with 2006, it became apparent tha…

medicine.medical_specialtyGynecologic oncologySurgical stagingGynecologic Surgical ProceduresGermanySurveys and QuestionnairesCytologyAntineoplastic Combined Chemotherapy ProtocolsmedicineCarcinomaHumansMulticenter Studies as TopicPelvic lymphadenectomyDiagnostic Techniques Obstetrical and GynecologicalNeoplasm StagingGynecologybusiness.industryData CollectionGeneral surgeryEndometrial cancerObstetrics and GynecologyProfessional PracticeGuidelinemedicine.diseaseHospitalsPeritoneal washingEndometrial NeoplasmsOncologyLymph Node ExcisionFemaleGuideline AdherencebusinessCarcinoma EndometrioidInternational Journal of Gynecologic Cancer
researchProduct

Oral vinorelbine in the treatment of non-small cell lung cancer: rationale and implications for patient management.

2007

Vinorelbine is an established treatment for advanced non-small cell lung cancer (NSCLC), both as a single agent and in combination chemotherapy. Recently, an oral form of this agent has been developed. Before accepting an established agent in a different administration form, rigorous testing is required to answer such questions as reliable bioavailability, continued safety and preservation of efficacy. In addition, an oral agent must provide patient convenience and acceptance, while being an economically sound approach. Oral vinorelbine was found to have acceptable and reliable pharmacokinetic profiles at clinically relevant dosage levels. Oral vinorelbine was found to have approximately 40…

medicine.medical_specialtyLung Neoplasmsmedicine.drug_classAdministration OralPharmacologyVinorelbineVinblastineRoute of administrationchemistry.chemical_compoundOral administrationCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsMedicineAntiemeticHumansPharmacology (medical)Randomized Controlled Trials as Topicbusiness.industryCombination chemotherapyVinorelbineAntineoplastic Agents PhytogenicCombined Modality TherapyGemcitabineCarboplatinBioavailabilitySurgerychemistryOral vinorelbine small cell lung cancer.businessmedicine.drugDrugs
researchProduct

A case of guillain-barre syndrome in a patient with non small cell lung cancer treated with chemotherapy

2006

Guillain-Barré Syndrome (GBS) is a demyelinating polyneuropathy of probable autoimmune pathogenesis characterized by rapidly progressive symmetric paralysis. In the literature some cases of GBS associated with anticancer chemotherapy are reported. We present a case of a 55-year old woman who complained of progressive motor deficit in four limbs, areflexia in lower limbs and facial nerve paralysis one week after beginning cisplatin-gemcitabine chemotherapy for metastatic lung cancer. The cerebrospinal fluid analysis showed a strong positive Pandy reaction with 435 mg/dl total protein. The electromyography and the electroneuronography established the diagnosis of inflammatory demyelinating po…

medicine.medical_specialtyLung Neoplasmsmedicine.medical_treatmentBone NeoplasmsGuillain-Barre SyndromeDeoxycytidineGastroenterologyPathogenesisCerebrospinal fluidCarcinoma Non-Small-Cell LungInternal medicineAntineoplastic Combined Chemotherapy ProtocolsElectroneuronographyParalysismedicineHumansPharmacology (medical)Lung cancerPharmacologyChemotherapyGuillain-Barre syndromebusiness.industryGuillain-Barré Syndrome neuropathy chemotherapy toxicity lung cancerImmunoglobulins IntravenousMiddle Agedmedicine.diseaseGemcitabineFacial nerveSurgeryInfectious DiseasesOncologyFemaleCisplatinmedicine.symptombusiness
researchProduct

Protocols for management of oral complications of chemotherapy and/or radiotherapy for oral cancer: Systematic review and meta-analysis current

2017

Background and Objectives Considering the high possibility of dentist consult a patient with oral complications of chemotherapy and/or radiotherapy for oral cancer because of the advances in this area, this study aims to systematically review the literature to identify and suggest effective and safe protocols for the managements of oral complications in oncology patients. Material and Methods TThe systematic review was designed by PICO and PRISMA including eligibility and exclusion criteria; the source of information and search strategy in PubMed according MeSH: “Mouth Neoplasms and Radiotherapy” and “Mouth Neoplasms and Drug Therapy” the period from 2010 to 2015; selection and data collect…

medicine.medical_specialtyMEDLINEDentistryAntineoplastic AgentsReview03 medical and health sciences0302 clinical medicinePharmacotherapyClinical ProtocolsmedicineMucositisHumansRadiation InjuriesIntensive care medicineGeneral DentistryMouth neoplasmOral Medicine and PathologyRadiotherapybusiness.industryChlorhexidine030206 dentistryOdds ratio:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseOtorhinolaryngology030220 oncology & carcinogenesisMeta-analysisRelative riskUNESCO::CIENCIAS MÉDICASMouth NeoplasmsSurgeryMouth DiseasesbusinessSystematic Reviews as Topicmedicine.drugMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Two consecutive clinical trials on cisplatin (CDDP), hepatic arterial infusion (HAI), and I.V. 5-fluorouracil (5-FU) chemotherapy for unresectable co…

1991

Several phase III clinical trials demonstrated that hepatic arterial chemotherapy for unresectable colorectal liver metastases is able to provide significantly higher response rates than those obtained by systemic route: in more than 500 patients collected from 6 randomized trials, the median values of objective response rates were 55% after fluoxuridine (FUdR) continuous hepatic arterial infusion (HAI) vs. 18.5% after FUdR or 5-fluorouracil (5-FU) intravenous (i.v.) chemotherapy. Furthermore, the majority of those studies reported that median survival increased in the patient subgroups treated with intrahepatic chemotherapy, even if not always statistically significant [1-6]. Certainly, FU…

medicine.medical_specialtyOrganoplatinum Compoundsmedicine.medical_treatmentPhases of clinical researchRectumGastroenterologyMetastasisHepatic arterial infusionInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansInfusions Intra-ArterialCisplatinChemotherapybusiness.industryLiver NeoplasmsGeneral MedicineMiddle Agedmedicine.diseaseSurgerySurvival RateClinical trialmedicine.anatomical_structureOncologyFluorouracilDrug EvaluationSurgeryFluorouracilColorectal NeoplasmsFloxuridinebusinessmedicine.drugJournal of Surgical Oncology
researchProduct

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

2010

Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up A. Okines, M. Verheij, W. Allum, D. Cunningham & A. Cervantes On behalf of the ESMO Guidelines Working Group* GI Clinical Trials Unit, Royal Marsden Hospital, Sutton, UK; Department of Radiation Oncology and Division of Cellular Biochemistry, The Netherlands Cancer Institute—Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands; Department of Surgery, Royal Marsden Hospital, London; Department of Medicine, Royal Marsden Hospital, Sutton, UK; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain

medicine.medical_specialtyPalliative careTreatment outcomeMeta-Analysis as TopicStomach NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsGastroscopyRadiation oncologyEpidemiologymedicineHumansNeoplasm MetastasisNeoplasm StagingRandomized Controlled Trials as TopicRadiotherapybusiness.industryIncidenceGeneral surgeryPalliative CareCancerHematologymedicine.diseaseCombined Modality TherapySurvival AnalysishumanitiesSurgeryEuropeClinical PracticeTreatment OutcomeOncologyClinical trials unitDiagnosis treatmentChemotherapy AdjuvantbusinessFollow-Up StudiesAnnals of Oncology
researchProduct

Primary extranodal non-Hodgkin lymphomas of the uterus and the breast: report of three cases

1995

The authors describe one case of a rare primitive non-Hodgkin lymphoma of the uterus, and two cases of primary non-Hodgkin lymphoma of the breast. Histologically, the uterine lymphoma, although clinically confined to the uterus, was a diffuse large cell lymphoma, group G according to the Working formulation for Clinical Usage. The two cases of breast lymphoma were a centrocytic-centroblastic and a lymphoplasmocytoid non-Hodgkin lymphoma, respectively. All cases were initally treated with radical surgery plus radiotherapy, but the first patient showed an early recurrence at distant sites, which required systemic cytotoxic chemotherapy. The patient with uterine non-Hodgkin lymphoma received a…

medicine.medical_specialtyPathologyWorking Formulationmedicine.medical_treatmentMammary glandUterusBreast NeoplasmsCHOPimmune system diseaseshemic and lymphatic diseasesAntineoplastic Combined Chemotherapy ProtocolsHumansMedicineRadical surgeryChemotherapybusiness.industryLymphoma Non-HodgkinGeneral MedicineMiddle Agedmedicine.diseaseCombined Modality TherapyLymphomaRadiation therapymedicine.anatomical_structureOncologyUterine NeoplasmsFemaleSurgeryLymphoma Large B-Cell DiffuseRadiologybusinessEuropean Journal of Surgical Oncology (EJSO)
researchProduct

Cytoreductive surgery and mitomycin C hyperthermic intraperitoneal chemotherapy with CO2 recirculation (HIPEC-CO2) for colorectal cancer peritoneal m…

2021

Peritoneal dissemination from colorectal cancer (CRC) has long been associated with unfavorable prognosis. However, in the last decades, the combination of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) was able to obtain up to 30% 5-year survival rate in selected centers. Despite the wide diffusion of CRS and HIPEC, until now, there are no clear recommendations on the drug of choice for HIPEC nor its technique, and safety and efficacy data of HIPEC regimens and techniques are lacking. We performed a retrospective analysis of a prospectively maintained database of 26 CRS and mitomycin C HIPEC with CO2 recirculation (HIPEC-CO2) for CRC peritoneal metastasis…

medicine.medical_specialtyPeritoneal metastasisColorectal cancerMitomycinSettore MED/18 - CHIRURGIA GENERALE2Hyperthermic Intraperitoneal Chemotherapy030230 surgery03 medical and health sciences0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansHyperthermiaAdverse effectSurvival ratePeritoneal NeoplasmsRetrospective StudiesCarcinomatosisHIPECbusiness.industryInducedMitomycin CCommon Terminology Criteria for Adverse EventsCytoreduction Surgical ProceduresHyperthermia InducedCarbon DioxidePrognosismedicine.diseaseColorectal cancerCombined Modality TherapyHIPEC-COSurgerySurvival Rate030220 oncology & carcinogenesisPeritoneal metastasisSurgeryHyperthermic intraperitoneal chemotherapyColorectal NeoplasmsbusinessCytoreductive surgeryUpdates in Surgery
researchProduct

Reduced-dose of doublet chemotherapy combined with anti-EGFR antibodies in vulnerable older patients with metastatic colorectal cancer: Data from the…

2022

Abstract Objectives To assess the toxicity patterns and effectiveness of doublet chemotherapy when administered at reduced doses of 20% (FOLFOX or FOLFIRI) in combination with anti-EGFR antibodies (cetuximab or panitumumab) in old, vulnerable patients with metastatic colorectal cancer (mCRC). Patients and methods We performed a retrospective observational study of RAS and BRAF wild-type, vulnerable patients aged ≥70 years with previously untreated mCRC. The primary endpoint was safety, and secondary endpoints were overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Results One hundred and eighteen patients were collected from 14 selected Italian centres.…

medicine.medical_specialtyReduced doseColorectal cancerLeucovorinCetuximabNeutropeniaGastroenterologyFOLFOXInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineClinical endpointHumansPanitumumabDoublet chemotherapyAnti-EGFRAgedCetuximabMetastatic colorectal cancerRectal Neoplasmsbusiness.industryPanitumumabAnti-EGFRs Doublet chemotherapy Metastatic colorectal cancer Reduced doses Vulnerable older patientsExanthemamedicine.diseaseRashVulnerable older patients.OncologyColonic NeoplasmsFOLFIRIFluorouracilGeriatrics and Gerontologymedicine.symptomColorectal Neoplasmsbusinessmedicine.drugJournal of Geriatric Oncology
researchProduct